MedTrace Logo

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain

NCT07568015 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-08-04

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and analgesic performance of the ReneuRx™ device in subjects with moderate to severe chronic lateral hip pain compared to subjects receiving treatment with corticosteroid injection in adults aged 22-80 years. Participants will attend study visits and complete quality of life questionnaires. Participants will be followed for approximately 6-12 months after the study procedure.

Conditions

  • Greater Trochanteric Pain Syndrome
  • Greater Trochanteric Pain Syndrome of Both Lower Limbs
  • Lateral Hip Pain

Interventions

DRUG

Triamcinolone acetate

A single 40mg Triamcinolone dose, prepared as 1ml of steroid mixed with 4ml of saline, of which 3-5ml is injected.

DEVICE

ReneuRx

ReneuRx will be injected around the trochanteric branches of the femoral nerve.

Sponsors & Collaborators

  • MCRA

    collaborator INDUSTRY

  • Brixton Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-27
Primary Completion
2027-11-01
Completion
2029-11-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07568015 on ClinicalTrials.gov